Are you prepared for Wrath of the Lich King? WoW Insider has you covered!

AOL Money & Finance

Posts with tag ctcm

Broadcasting profits in Russia with CTC Media (CTCM)

"Many of the industries that we think of as 'mature' in the U.S. are still in their infancy in Russia," notes global expert John Christy.

In his Forbes International Investment Report, he notes, "Advertising is a perfect example. Overall, the Russian ad market is growing at a 25%-30% clip." Here, he looks at CTC Media (NASDAQ: CTCM), one of the leading TV broadcasters in Russia.

"In 2007, total advertising spending in Russia was approximately $9 billion versus just $1.1 billion back in 2000. To put things in perspective, consider that in the U.K., Europe's largest ad market, spending is roughly $22 billion.

"With more than twice the population of the U.K., Russia's advertising market is less than half its size. Of course, it will take a very long time for Russia's economy to become as developed as Britain's but there is clearly a lot of room for growth.

"Television companies will be a prime beneficiary of this trend. TV accounts for about half of all advertising spending in Russia, or about $4.4 billion. And television advertising has been growing at 40% annually, an even faster pace than that of ad spending overall.

"One of the easiest ways for investors to tap into this growth is through CTC Media. The Moscow-based company is Russia's fourth-biggest broadcaster, with an 11.3% audience share.

Continue reading Broadcasting profits in Russia with CTC Media (CTCM)

Analyst initiations: CTCM, CALD and SGEN

MOST NOTEWORTHY: CTC Media, Callidus Software and Seattle Genetics were today's noteworthy initiations:
  • Merrill initiated CTC Media (NASDAQ: CTCM) with a Buy rating, citing the company's healthy ad growth outlook and substantial barriers to entry.
  • B. Riley initiated Callidus Software (NASDAQ: CALD) with a Buy rating and $7 target and believes the company's growing On-Demand offering is being overlooked by investors.
  • Seattle Genetics (NASDAQ: SGEN) was assumed with an Overweight rating at JP Morgan. The firm views the company as an attractive investment opportunity given the company's growing pipeline of differentiated antibody therapies and partnership with Genentech (NYSE: DNA).
OTHER INITIATIONS:
  • Cowen initiated Boston Scientific (NYSE: BSX) with a Neutral rating and St. Jude Medical (NYSE: STJ) with an Outperform rating.
  • Lehman initiated UDR Inc (NYSE: UDR) with an Equal Weight rating.

Symbol Lookup
IndexesChangePrice

Last updated: October 13, 2008: 06:26 PM

BloggingStocks Exclusives

Hot Stocks

BloggingStocks Featured Video

TheFlyOnTheWall.com Headlines

WalletPop Headlines

AOL Business News

Latest from BloggingBuyouts

Sponsored Links

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance